secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001104659-22-073906
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel receives Paragraph IV notice from Annora for generic TAVALISSE; intends to defend patents
--------------------------------------------------------------------------------

- Annora Pharma filed ANDA with FDA for generic fostamatinib tablets (100mg and 150mg base).
- Notice letter includes Paragraph IV certifications alleging Rigel's TAVALISSE patents are invalid or not infringed.
- Rigel states it will vigorously enforce its intellectual property rights related to TAVALISSE.
- TAVALISSE is Rigel's sole approved product; generic entry would materially impact revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922073906/0001104659-22-073906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922073906/tm2219181d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-073906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer